Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Assetmark Inc.

Assetmark Inc. lowered its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 9.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,891 shares of the specialty pharmaceutical company’s stock after selling 524 shares during the quarter. Assetmark Inc.’s holdings in Collegium Pharmaceutical were worth $189,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of COLL. Caxton Associates LP acquired a new position in Collegium Pharmaceutical during the first quarter worth approximately $1,730,000. Foundry Partners LLC acquired a new stake in shares of Collegium Pharmaceutical during the 2nd quarter worth $492,000. O Shaughnessy Asset Management LLC raised its position in shares of Collegium Pharmaceutical by 159.3% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 45,735 shares of the specialty pharmaceutical company’s stock worth $1,775,000 after buying an additional 28,100 shares during the period. Vanguard Group Inc. boosted its holdings in Collegium Pharmaceutical by 0.8% in the first quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after acquiring an additional 17,942 shares during the last quarter. Finally, Squarepoint Ops LLC grew its position in Collegium Pharmaceutical by 194.5% during the second quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock valued at $3,553,000 after acquiring an additional 72,874 shares during the period.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the transaction, the executive vice president now owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. This represents a 15.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the sale, the executive vice president now owns 120,161 shares of the company’s stock, valued at approximately $4,602,166.30. This trade represents a 13.81 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Trading Down 2.3 %

COLL opened at $29.58 on Friday. The firm’s 50 day moving average is $36.36 and its 200-day moving average is $35.01. Collegium Pharmaceutical, Inc. has a 52-week low of $24.61 and a 52-week high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The firm has a market capitalization of $953.96 million, a P/E ratio of 12.75 and a beta of 0.95.

Analyst Ratings Changes

COLL has been the topic of a number of research reports. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. HC Wainwright lifted their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Truist Financial raised their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus price target of $42.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.